Nanexa AB (publ) today announces that the Annual Report for 2025 has been published and is available on the company's website Nanexa AB - Financial reports.
During the year, Nanexa has made significant progress in the NEX-22 project, where the development of monthly and quarterly formulations of semaglutide demonstrated promising preclinical results in the first quarter of 2026. In December, a licence and option agreement was also signed with Moderna, providing Nanexa with an upfront payment of USD 3 million and the potential to receive up to USD 500 million in milestone payments and future royalty revenues.
“The agreement with Moderna is a breakthrough for our business strategy and confirms the strength of our PharmaShell® technology. At the same time, we have taken important steps within the NEX-22 project, now also including semaglutide, and we see that the project has great market potential,” says David Westberg, CEO of Nanexa.